These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 29321176

  • 1. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
    MacIsaac RJ, Thomas MC.
    Clin J Am Soc Nephrol; 2018 Feb 07; 13(2):321-323. PubMed ID: 29321176
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Potential kidney protective effects of glucagon-like peptide-1 receptor agonists.
    Trevella P, Ekinci EI, MacIsaac RJ.
    Nephrology (Carlton); 2024 Aug 07; 29(8):457-469. PubMed ID: 39030739
    [Abstract] [Full Text] [Related]

  • 6. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.
    Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR.
    Nat Rev Nephrol; 2021 Apr 07; 17(4):227-244. PubMed ID: 33219281
    [Abstract] [Full Text] [Related]

  • 7. Are SGLT2 Inhibitors Ready for Prime Time for CKD?
    Pecoits-Filho R, Perkovic V.
    Clin J Am Soc Nephrol; 2018 Feb 07; 13(2):318-320. PubMed ID: 28893920
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Incretins in the Therapy of Diabetic Kidney Disease.
    Przezak A, Bielka W, Pawlik A.
    Int J Mol Sci; 2021 Nov 15; 22(22):. PubMed ID: 34830194
    [Abstract] [Full Text] [Related]

  • 10. Incretin and glucagon receptor polypharmacology in chronic kidney disease.
    McFarlin BE, Duffin KL, Konkar A.
    Am J Physiol Endocrinol Metab; 2024 Jun 01; 326(6):E747-E766. PubMed ID: 38477666
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H, Zhou B, Xu G.
    Cardiovasc Diabetol; 2017 May 16; 16(1):65. PubMed ID: 28511711
    [Abstract] [Full Text] [Related]

  • 13. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
    van Baar MJB, van Raalte DH.
    Curr Opin Nephrol Hypertens; 2020 Jan 16; 29(1):103-111. PubMed ID: 31714285
    [Abstract] [Full Text] [Related]

  • 14. The potential for renoprotection with incretin-based drugs.
    Tanaka T, Higashijima Y, Wada T, Nangaku M.
    Kidney Int; 2014 Oct 16; 86(4):701-11. PubMed ID: 25007170
    [Abstract] [Full Text] [Related]

  • 15. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
    Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Esposito K.
    Diabetes Obes Metab; 2019 Aug 16; 21(8):1790-1800. PubMed ID: 30969018
    [Abstract] [Full Text] [Related]

  • 16. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
    Hiramatsu T, Ito H, Okumura S, Asano Y, Iguchi D, Furuta S.
    Diab Vasc Dis Res; 2020 Aug 16; 17(6):1479164120971220. PubMed ID: 33371732
    [Abstract] [Full Text] [Related]

  • 17. Physiology and pathophysiology of incretins in the kidney.
    von Websky K, Reichetzeder C, Hocher B.
    Curr Opin Nephrol Hypertens; 2014 Jan 16; 23(1):54-60. PubMed ID: 24257158
    [Abstract] [Full Text] [Related]

  • 18. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
    Muskiet MH, Smits MM, Morsink LM, Diamant M.
    Nat Rev Nephrol; 2014 Feb 16; 10(2):88-103. PubMed ID: 24375052
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological Management of Diabetic Nephropathy.
    Papademetriou V, Alataki S, Stavropoulos K, Papadopoulos C, Bakogiannis K, Tsioufis K.
    Curr Vasc Pharmacol; 2020 Feb 16; 18(2):139-147. PubMed ID: 30961500
    [Abstract] [Full Text] [Related]

  • 20. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.
    Yamada S, Tanabe J, Ogura Y, Nagai Y, Sugaya T, Ohata K, Natsuki Y, Ichikawa D, Watanabe S, Inoue K, Hoshino S, Kimura K, Shibagaki Y, Kamijo-Ikemori A.
    Clin Exp Nephrol; 2021 Apr 16; 25(4):365-375. PubMed ID: 33409761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.